Japanese pharmaceutical company Kyowa Kirin Co Ltd (TSE:4151) announced on Thursday the launch of a five year strategic research alliance with Harvard University to help accelerate discovery and early-stage innovation in translational biomedical science.
By creating opportunities for formal scientific collaboration, the alliance aims to leverage industry insight and drug development expertise to advance biomedical innovations developed in Harvard labs toward the clinical development of important new therapies.
Projects under the alliance will be initiated by Harvard's life-science faculty through a proposal process. Projects selected for funding and scientific collaboration will be identified by a Joint Steering Committee, comprising membership from both Harvard and Kyowa Kirin.
Adagio Therapeutics begins global clinical trial of ADG20 for the treatment of COVID-19
UK expands COVID-19 vaccine combination trial to over-50s
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India
SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Frankel Named to Precision BioSciences B oard of Directors
Sobi launches phase 3 trial of efanesoctocog alfa in children with haemophilia A
Zealand Pharma and Boehringer Ingelheim to conduct Phase 2 trials of BI 456906 in obesity and NASH